Domini Bryer

649 total citations
14 papers, 486 citations indexed

About

Domini Bryer is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Domini Bryer has authored 14 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 5 papers in Hematology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Domini Bryer's work include Rheumatoid Arthritis Research and Therapies (11 papers), Systemic Lupus Erythematosus Research (8 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Domini Bryer is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Systemic Lupus Erythematosus Research (8 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Domini Bryer collaborates with scholars based in United Kingdom and Egypt. Domini Bryer's co-authors include Paul Emery, Maya H Buch, Sarah Bingham, Jo White, Victoria Bejarano, Mark Quinn, Helena Marzo‐Ortega, Yohei Seto, Laura C. Coates and Lorna Cawkwell and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Clinical & Experimental Immunology.

In The Last Decade

Domini Bryer

14 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Domini Bryer United Kingdom 8 408 174 165 57 55 14 486
E. Keystone Canada 8 259 0.6× 86 0.5× 108 0.7× 48 0.8× 59 1.1× 26 357
L Pepper United Kingdom 9 231 0.6× 128 0.7× 229 1.4× 74 1.3× 68 1.2× 9 503
Emeli Lundström Sweden 8 367 0.9× 171 1.0× 41 0.2× 148 2.6× 62 1.1× 11 464
D M Gerlag Netherlands 6 271 0.7× 135 0.8× 46 0.3× 132 2.3× 77 1.4× 11 418
Antônio Carlos Ximenes Brazil 11 434 1.1× 146 0.8× 185 1.1× 79 1.4× 124 2.3× 22 504
Karen I. Maijer Netherlands 11 251 0.6× 107 0.6× 65 0.4× 64 1.1× 27 0.5× 13 396
Concepción Moll Spain 7 195 0.5× 105 0.6× 41 0.2× 54 0.9× 31 0.6× 12 342
Isaac Abadi Venezuela 8 349 0.9× 247 1.4× 43 0.3× 78 1.4× 20 0.4× 9 435
Andrew Chubick United States 6 269 0.7× 154 0.9× 104 0.6× 105 1.8× 143 2.6× 8 456
G. Bonilla Spain 4 294 0.7× 135 0.8× 46 0.3× 80 1.4× 142 2.6× 10 436

Countries citing papers authored by Domini Bryer

Since Specialization
Citations

This map shows the geographic impact of Domini Bryer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domini Bryer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domini Bryer more than expected).

Fields of papers citing papers by Domini Bryer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domini Bryer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domini Bryer. The network helps show where Domini Bryer may publish in the future.

Co-authorship network of co-authors of Domini Bryer

This figure shows the co-authorship network connecting the top 25 collaborators of Domini Bryer. A scholar is included among the top collaborators of Domini Bryer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Domini Bryer. Domini Bryer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
Coulthard, Lydia, Janina Geiler, Leigh D Church, et al.. (2012). Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clinical & Experimental Immunology. 170(1). 36–46. 41 indexed citations
4.
Das, Sudipto, Sarah Horton, Edward M Vital, et al.. (2012). THU0089 Response to abatacept and tocilizumab in patients who had failed rituximab– initial single centre experience. Annals of the Rheumatic Diseases. 71. 183–183. 1 indexed citations
5.
Coates, Laura C., Lorna Cawkwell, Alexander N. Bennett, et al.. (2008). Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Lara D. Veeken. 47(6). 897–900. 64 indexed citations
6.
Wakefield, Richard J., Jane Freeston, E. Hensor, et al.. (2007). Delay in imaging versus clinical response: A rationale for prolonged treatment with anti–tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Care & Research. 57(8). 1564–1567. 61 indexed citations
7.
Buch, Maya H, Sarah Bingham, Domini Bryer, & Paul Emery. (2007). Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Lara D. Veeken. 46(7). 1153–1156. 77 indexed citations
8.
Bryer, Domini & Jo White. (2007). Rheumatoid arthritis in practice. Independent Nurse. 2007(3). 4 indexed citations
9.
Coates, Laura C., Lorna Cawkwell, Alexander N. Bennett, et al.. (2007). Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Annals of the Rheumatic Diseases. 67(5). 717–719. 43 indexed citations
10.
Buch, Maya H, Sarah Bingham, Victoria Bejarano, et al.. (2007). Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis Care & Research. 57(3). 448–453. 63 indexed citations
11.
Bryer, Domini. (2006). Influences that drive clinical decision making among junior rheumatology nurses: A qualitative study. Musculoskeletal Care. 4(4). 223–232. 1 indexed citations
12.
Bryer, Domini. (2006). Influences that drive clinical decision-making among rheumatology nurses. Part 1: literature review. Musculoskeletal Care. 4(3). 130–139. 2 indexed citations
13.
Buch, Maya H, Yohei Seto, Sarah Bingham, et al.. (2005). C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept. Arthritis & Rheumatism. 52(1). 42–48. 93 indexed citations
14.
Heijde, D. van der, Andrew Gough, Joachim R. Kalden, et al.. (2004). 31. SWITCHING BIOLOGICS AFTER INITIAL ANTI-TUMOUR NECROSIS FACTOR-α FAILURE; SUCCESS WITH FURTHER TNF-α ANTAGONISM BUT FAILURE ON SUBSEQUENT INTERLEUKIN-1 RECEPTOR ANTAGONIST. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Keystone Breakdown of academic impact, for papers by L Pepper Breakdown of academic impact, for papers by Emeli Lundström Breakdown of academic impact, for papers by D M Gerlag Breakdown of academic impact, for papers by Antônio Carlos Ximenes Breakdown of academic impact, for papers by Karen I. Maijer Breakdown of academic impact, for papers by Concepción Moll Breakdown of academic impact, for papers by Isaac Abadi Breakdown of academic impact, for papers by Andrew Chubick Breakdown of academic impact, for papers by G. Bonilla
Rankless by CCL
2026